{"title":"CD20/CD3 双特异性抗体在治疗自身免疫性疾病方面的治疗潜力。","authors":"Hongpeng Huang, Xuetao Wei","doi":"10.1515/rir-2024-0029","DOIUrl":null,"url":null,"abstract":"<p><p>Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"5 4","pages":"209-216"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720466/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases.\",\"authors\":\"Hongpeng Huang, Xuetao Wei\",\"doi\":\"10.1515/rir-2024-0029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.</p>\",\"PeriodicalId\":74736,\"journal\":{\"name\":\"Rheumatology and immunology research\",\"volume\":\"5 4\",\"pages\":\"209-216\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11720466/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology and immunology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/rir-2024-0029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and immunology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/rir-2024-0029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
自身免疫性疾病源于免疫系统功能紊乱，免疫细胞错误地攻击人体自身组织，导致全身性疾病或局部病变，如系统性红斑狼疮（SLE）和类风湿性关节炎（RA）。自反应性 B 细胞在许多自身免疫性疾病的发病机制中起着关键作用，临床前研究和临床研究都表明，使用抗 CD20 单克隆抗体（mAb）清除 B 细胞可有效缓解疾病进展。最近，以 CD20/CD3 为靶点的双特异性抗体（bsAb）在治疗各种血液恶性肿瘤方面取得了显著的临床疗效。鉴于其相似的 B 细胞细胞毒性机制，CD20/CD3 双特异性抗体疗法可能会显著改善许多自身免疫性疾病的治疗，为患者提供一种新的治疗选择。这篇简明综述旨在总结 CD20/CD3 bsAbs 的最新研究成果，并讨论它们在治疗自身免疫性疾病方面的潜力。
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases.
Autoimmune diseases arise from immune system dysfunction that immune cells mistakenly attack the body's own tissues, resulting in systemic disorders or localized lesions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Autoreactive B cells play a critical role in the pathogenesis of many autoimmune diseases and B cell depletion using anti-CD20 monoclonal antibody (mAb) has been shown to effectively mitigate disease progression in both preclinical and clinical studies. Recently, bispecific antibody (bsAb) targeting CD20/CD3 have demonstrated substantial clinical benefits in the treatment of various hematologic malignancies. Given their similar B cell cytotoxic mechanism, CD20/CD3 bsAb therapy may offer significant improvements in the management of many autoimmune diseases, providing a novel therapeutic option for patients. This concise review aims to summarize recent findings on CD20/CD3 bsAbs and discuss their potential in treating autoimmune diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
